Clinical implications of microRNAs in human glioblastoma

Masahiro Mizoguchi, Yanlei Guan, Koji Yoshimoto, Nobuhiro Hata, Toshiyuki Amano, Akira Nakamizo, Tomio Sasaki

Research output: Contribution to journalReview article

43 Citations (Scopus)

Abstract

Glioblastoma (GBM) is one of the most common and dismal brain tumors in adults. Further elucidation of the molecular pathogenesis of GBM is mandatory to improve the overall survival of patients. A novel small non-coding RNA molecule, microRNA (miRNA), appears to represent one of the most attractive target molecules contributing to the pathogenesis of various types of tumors. Recent global analyses have revealed that several miRNAs are clinically implicated in GBM, with some reports indicating the association of miRNA dysregulation with acquired temozolomide (TMZ) resistance. More recent studies have revealed that miRNAs could play a role in cancer stem cell (CSC) properties, contributing to treatment resistance. In addition, greater impact might be expected from miRNA-targeted therapies based on tumor-derived exosomes that contain numerous functional miRNAs, which could be transferred between tumor cells and surrounding structures. Tumor-derived miRNAs are now considered to be a novel molecular mechanism promoting the progression of GBM. Establishment of miRNA-targeted therapies based on miRNA dysregulation of CSCs could provide effective therapeutic strategies for TMZ-resistant GBM. Recent progress has revealed that miRNAs are not only putative biological markers for diagnosis, but also one of the most promising targets for GBM treatment. Here in, we summarize the translational aspects of miRNAs in the diagnosis and treatment of GBM.

Original languageEnglish
Article numberArticle 00019
JournalFrontiers in Oncology
Volume3 FEB
DOIs
Publication statusPublished - Dec 24 2013

Fingerprint

Glioblastoma
MicroRNAs
temozolomide
Neoplasms
Therapeutics
Exosomes
Small Untranslated RNA
Neoplastic Stem Cells
Brain Neoplasms
Biomarkers
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Mizoguchi, M., Guan, Y., Yoshimoto, K., Hata, N., Amano, T., Nakamizo, A., & Sasaki, T. (2013). Clinical implications of microRNAs in human glioblastoma. Frontiers in Oncology, 3 FEB, [Article 00019]. https://doi.org/10.3389/fonc.2013.00019

Clinical implications of microRNAs in human glioblastoma. / Mizoguchi, Masahiro; Guan, Yanlei; Yoshimoto, Koji; Hata, Nobuhiro; Amano, Toshiyuki; Nakamizo, Akira; Sasaki, Tomio.

In: Frontiers in Oncology, Vol. 3 FEB, Article 00019, 24.12.2013.

Research output: Contribution to journalReview article

Mizoguchi, M, Guan, Y, Yoshimoto, K, Hata, N, Amano, T, Nakamizo, A & Sasaki, T 2013, 'Clinical implications of microRNAs in human glioblastoma', Frontiers in Oncology, vol. 3 FEB, Article 00019. https://doi.org/10.3389/fonc.2013.00019
Mizoguchi, Masahiro ; Guan, Yanlei ; Yoshimoto, Koji ; Hata, Nobuhiro ; Amano, Toshiyuki ; Nakamizo, Akira ; Sasaki, Tomio. / Clinical implications of microRNAs in human glioblastoma. In: Frontiers in Oncology. 2013 ; Vol. 3 FEB.
@article{cbfe4bc1d6f44f6fb5468597326d29fa,
title = "Clinical implications of microRNAs in human glioblastoma",
abstract = "Glioblastoma (GBM) is one of the most common and dismal brain tumors in adults. Further elucidation of the molecular pathogenesis of GBM is mandatory to improve the overall survival of patients. A novel small non-coding RNA molecule, microRNA (miRNA), appears to represent one of the most attractive target molecules contributing to the pathogenesis of various types of tumors. Recent global analyses have revealed that several miRNAs are clinically implicated in GBM, with some reports indicating the association of miRNA dysregulation with acquired temozolomide (TMZ) resistance. More recent studies have revealed that miRNAs could play a role in cancer stem cell (CSC) properties, contributing to treatment resistance. In addition, greater impact might be expected from miRNA-targeted therapies based on tumor-derived exosomes that contain numerous functional miRNAs, which could be transferred between tumor cells and surrounding structures. Tumor-derived miRNAs are now considered to be a novel molecular mechanism promoting the progression of GBM. Establishment of miRNA-targeted therapies based on miRNA dysregulation of CSCs could provide effective therapeutic strategies for TMZ-resistant GBM. Recent progress has revealed that miRNAs are not only putative biological markers for diagnosis, but also one of the most promising targets for GBM treatment. Here in, we summarize the translational aspects of miRNAs in the diagnosis and treatment of GBM.",
author = "Masahiro Mizoguchi and Yanlei Guan and Koji Yoshimoto and Nobuhiro Hata and Toshiyuki Amano and Akira Nakamizo and Tomio Sasaki",
year = "2013",
month = "12",
day = "24",
doi = "10.3389/fonc.2013.00019",
language = "English",
volume = "3 FEB",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Clinical implications of microRNAs in human glioblastoma

AU - Mizoguchi, Masahiro

AU - Guan, Yanlei

AU - Yoshimoto, Koji

AU - Hata, Nobuhiro

AU - Amano, Toshiyuki

AU - Nakamizo, Akira

AU - Sasaki, Tomio

PY - 2013/12/24

Y1 - 2013/12/24

N2 - Glioblastoma (GBM) is one of the most common and dismal brain tumors in adults. Further elucidation of the molecular pathogenesis of GBM is mandatory to improve the overall survival of patients. A novel small non-coding RNA molecule, microRNA (miRNA), appears to represent one of the most attractive target molecules contributing to the pathogenesis of various types of tumors. Recent global analyses have revealed that several miRNAs are clinically implicated in GBM, with some reports indicating the association of miRNA dysregulation with acquired temozolomide (TMZ) resistance. More recent studies have revealed that miRNAs could play a role in cancer stem cell (CSC) properties, contributing to treatment resistance. In addition, greater impact might be expected from miRNA-targeted therapies based on tumor-derived exosomes that contain numerous functional miRNAs, which could be transferred between tumor cells and surrounding structures. Tumor-derived miRNAs are now considered to be a novel molecular mechanism promoting the progression of GBM. Establishment of miRNA-targeted therapies based on miRNA dysregulation of CSCs could provide effective therapeutic strategies for TMZ-resistant GBM. Recent progress has revealed that miRNAs are not only putative biological markers for diagnosis, but also one of the most promising targets for GBM treatment. Here in, we summarize the translational aspects of miRNAs in the diagnosis and treatment of GBM.

AB - Glioblastoma (GBM) is one of the most common and dismal brain tumors in adults. Further elucidation of the molecular pathogenesis of GBM is mandatory to improve the overall survival of patients. A novel small non-coding RNA molecule, microRNA (miRNA), appears to represent one of the most attractive target molecules contributing to the pathogenesis of various types of tumors. Recent global analyses have revealed that several miRNAs are clinically implicated in GBM, with some reports indicating the association of miRNA dysregulation with acquired temozolomide (TMZ) resistance. More recent studies have revealed that miRNAs could play a role in cancer stem cell (CSC) properties, contributing to treatment resistance. In addition, greater impact might be expected from miRNA-targeted therapies based on tumor-derived exosomes that contain numerous functional miRNAs, which could be transferred between tumor cells and surrounding structures. Tumor-derived miRNAs are now considered to be a novel molecular mechanism promoting the progression of GBM. Establishment of miRNA-targeted therapies based on miRNA dysregulation of CSCs could provide effective therapeutic strategies for TMZ-resistant GBM. Recent progress has revealed that miRNAs are not only putative biological markers for diagnosis, but also one of the most promising targets for GBM treatment. Here in, we summarize the translational aspects of miRNAs in the diagnosis and treatment of GBM.

UR - http://www.scopus.com/inward/record.url?scp=84884273390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884273390&partnerID=8YFLogxK

U2 - 10.3389/fonc.2013.00019

DO - 10.3389/fonc.2013.00019

M3 - Review article

AN - SCOPUS:84884273390

VL - 3 FEB

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

M1 - Article 00019

ER -